RegulatoryOfficial
FDA approves Lembaz, first drug shown to extend survival in infantile-onset Niemann-Pick type C
🇺🇸 FDA · Tue 17 Nov 2026
Adrabetadex, an intrathecal injection with a boxed warning for hearing impairment, is cleared for patients weighing at least 7 kg whose neurological symptoms began before age 6.
The US Food and Drug Administration has approved Lembaz (adrabetadex) injection to reduce the risk of death in adult and paediatric patients with Niemann-Pick disease type C (NPC). Eligible patients must weigh at least 7 kg (about 15 lb) and have had neurological symptoms begin before age 6, known as infantile-onset NPC. The agency describes it as the first treatment shown to help people with this severe form of the disease live longer.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (FDA). AI-assisted; check the source before acting.
More Regulatory
All →
EEA Joint Committee extends three EU feed additive rules to Iceland and Norway
🇪🇺 EUR-Lex · Thu 19 Nov 2026
Health Canada lists Class II recall of Stryker's Blueprint shoulder-planning software over two bugs
🇨🇦 Health Canada · Wed 18 Nov 2026
FDA approves Infilbray, first treatment for neurological symptoms of Type 3 Gaucher disease
🇺🇸 FDA · Wed 18 Nov 2026
INFARMED lifts suspension of Limeciclina Atral 408 mg capsules after bioequivalence shown
🇵🇹 INFARMED · Wed 18 Nov 2026
Commission publishes minutes of SCHEER working group meeting on brain stimulators
🇪🇺 European Commission (DG SANTE) · Wed 18 Nov 2026
AIFA reminds sponsors how to pay Annual Safety Report evaluation fee
🇮🇹 AIFA · Wed 18 Nov 2026